Peptide Receptor Radionuclide Therapy using somatostatin analogs : preclinical tumor parameters modulation for potential dose optimization
(2012)
Files
PhD_Hanin_vRC106.pdf
Restricted Access - Adobe PDF
- 31.87 MB
Details
- Authors
- Supervisors
- Abstract
- (en) Neuroendocrine tumors express somatostatin receptors at the cell surface. In molecular imaging, this property is used for diagnostic procedures, by targeting these receptors with somatostatin analogs labeled with monophotonic emitters (such as 111In), or positron emitters (68Ga). In addition, the level of uptake noticed in these tumors allows the use of somatostatin receptor targeting for therapeutic purposes by labeling the peptides with beta emitters, mainly 177Lu and 90Y, in goal to deliver sufficient dose to tumors. This procedure is known as «Peptide Receptor Radionuclide Therapy» (PRRT). The optimization of such procedure focused for the last decade on the protection of critical organs, i.e. kidneys and bone marrow. Using dosimetry and specific kidney protection regimens such as amino acid infusions, the injected activity can be patient-tailored for optimization of dose to tumors. The aim of these studies is to focus on tumor parameters that could potentially be involved in tumor analog uptake, in goal to modulate these. By extension, the final purpose is to increase tumor analog uptake by varying the parameters, to increase delivered tumor dose, and by extension, tumor response. The successive factors analyzed are flow (chapter 2), homologous modulation by cold analog (chapter 3), heterologous modulation by interferon alpha (chapter 4) and impact of nuclide choice on dosimetry (chapter 5). Chapters 1 and 6 respectively introduces the subject and concludes.
- Affiliations
Citations
Hanin, F.-X. (2012). Peptide Receptor Radionuclide Therapy using somatostatin analogs : preclinical tumor parameters modulation for potential dose optimization. https://hdl.handle.net/2078.5/35954